ClinicalTrials.gg
RecruitingNCT06373471IMPROVEUpdated Apr 18, 2024

Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment

An interventional study of Comprehensive geriatric assessment (CGA) and treatment in Hematologic Malignancy, Treatment Adherence and Treatment Complication, sponsored by Odense University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Odense University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Hematologic Neoplasms with a site in Denmark — 12 open to participants now, 13 under way, 2 of them phase 3. Hematologic Neoplasms · Denmark.

Planned enrollment
10th of 21
152 · median 110
Started
2024
with 2 others
No phase
7 of 26
2 open now
Primary completion
2026-03
later than 1 of 12 live
Registered
20th of 26
by date
Lead sponsor
3 of 26
Odense University Hospital

Among the 26 studies in Hematologic Neoplasms with a site in Denmark, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 with no phase, reaches primary completion later than 1 of the 12 other live ones, and was the 20th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

12 of the 26 studies in Hematologic Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hematologic Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

The Improve study is a randomized controlled trial investigating the efficacy of adding comprehensive geriatric assessment and treatment to standard of care compared with standard of care in older, frail patients with hematological cancer. The investigators aim to recruit 152 study participants who will be randomized 1:1 to intervention- or control group. Study participants in the intervention group will receive the intervention comprehensive geriatric assessment and treatment integrated in the cancer treatment. Study participants in the control group will receive cancer treatment and evaluation of comorbidity and frailty as is usual standard at Department of Hematology. Primary endpoint is elderly functional Index at 12 weeks.

Read the detailed description

RESEARCH PLAN

STUDY DESIGN IMPROVE aims to investigate the efficacy of adding comprehensive geriatric assessment (CGA) and treatment to standard of care compared with standard of care in older, frail patients with hematological cancer. The investigators aim to recruit 152 study participants who will be randomized 1:1 to intervention- or control group. Study participants in the intervention group will receive the intervention CGA and treatment integrated in the cancer treatment. Study participants in the control group will receive cancer treatment and evaluation as well as management of comorbidity, frailty and needs as is the current standard at Departments of Hematology.

PARTICIPANTS AND TIMELINES One hundred and fifty two patients complying with inclusion and exclusion criteria detailed below will be recruited at participating Hematological Departments in Denmark. Study period is 52 weeks for each study participant.

INTERVENTIONS AND ASSESSMENTS Hematological treatment plan Study participants will be given a hematological cancer treatment plan according to standard guidelines at the discretion of the treating physician at the Department of Hematology. The hematological treatment plan will not be altered because of participation in IMPROVE study. Data on whether the cancer treatment is prescribed with a reduced dose-intensity due to frailty or later reduced due to toxicity will be collected.

CGA and treatment CGA and treatment will be performed before or after initiation of hematological cancer treatment, and within 6 weeks from inclusion. Performing CGA shall not delay initiation of hematological cancer treatment if immediate treatment is necessary. A geriatrician together with a geriatric nurse will perform CGA at the Department of Geriatric Medicine. CGA is more thoroughly described elsewhere in this report. Based on CGA findings, the geriatrician will initiate relevant further investigation(s), intervention(s) and treatment(s) if indicated.

Assessment of functional status The investigators will record the patients exercise habits via a short interview with the patient. The interview contains two questions concerning exercise habits derived from the Survey of Health, Ageing and Retirement in Europe (SHARE). Furthermore objective simple physical muscle strength tests will be applied to assess upper and lower extremity functioning.

Physical tests Physical tests will be assessed at baseline and at 12 and 26 weeks follow-up. Physical tests will be 30 seconds chair stand test (30s-CST) and handgrip strength

Treatment toxicity and adherence to the hematological treatment plan

Data will be collected at the beginning of each treatment cycle until 26 weeks after inclusion. The following data will be collected:

  • Treatment type.
  • Whether the treatment is a standard regimen, a dose-intensity reduced regimen or a study treatment from another clinical trail.
  • Whether the hematological treatment plan has been changed, including reduction of dosage, delay of treatment or preterm end of treatment and the reason for change of treatment plan.
  • Treatment toxicity using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCICTCAE v5.0) for selected groups of toxicity
  • Date and reason for discontinuation of cancer treatment until treatment completion or 26 weeks after initiation, whichever comes first.

Review of medications Information about polypharmacy (more than 5 daily drugs) will be collected from patients´ personal electronic file of prescriptions and medication purchases at baseline and at 12- and 26-week follow-up.

Hospitalization and survival Patients will be followed through a review of medical records for number and duration of unplanned hospitalizations and overall, and cancer-specific survival at 26- and 52-week follow-up.

03

Conditions studied

  • Hematologic Malignancy
  • Treatment Adherence
  • Treatment Complication
  • Frailty
  • Quality of Life

Keywords

  • Comprehensive Geriatric Assessment
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥70 years
  • New diagnosis or progression/relapse of acute leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, chronic myelomonocytic leukemia or myelofibrosis
  • Scheduled systemic cancer treatment or initiated systemic cancer treatment within 6 weeks
  • Geriatric 8 frailty score of ≤14 at screening
  • > 6 months
  • Not hospitalized at the time of inclusion

Exclusion criteria

Exclusion Criteria:

  • Current systemic treatment for other coexisting cancer. Patients receiving anti-hormone treatment for breast cancer or prostate cancer are not excluded, if no evidence of disease progression (radiological/biochemical) in past 3 months or if treatment is adjuvant.
  • Having consulted a geriatric outpatient clinic past 6 months
  • Patients in need of specialized neuro-rehabilitation
  • Unable to understand Danish
  • Unable to give written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Comprehensive Geriatric Assessment and treatment

    Other: Comprehensive geriatric assessment (CGA) and treatment

  • No intervention
    Control

    Standard hematological evaluation of comorbidity and needs during hematological cancer treatment.

Interventions

  • OtherComprehensive geriatric assessment (CGA) and treatment

    CGA and treatment is as an outpatient evaluation by a geriatric medical specialist and nurse. Specific CGA components in this study include: * Assessment of comorbidity and treatments * Review of medications including potential adjustment * Assessment of current symptoms and health related issues including geriatric syndromes such as depression, dementia, delirium, nutritional problems, falls and fatigue * Objective examination including blood tests and electrocardiogram * Assessment of activities of daily living (ADL) and instrumental ADL through standardized questionnaires * Assessment of domestic conditions, including need for assistance * Assessment of physical function Based on findings, the geriatrician will initiate relevant interventions and follow-up as required

06

What researchers measure

Primary outcomes

  1. Elderly functional Index

    The Elderly Functional Index (ELFI) is calculated using the physical functioning, role functioning, and social functioning of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) core 30, and the mobility item of the EORTC-QLQ-elderly 14 (ELD14) questionnaire. ELFI is calculated at baseline and at 12- and 26- week follow-up. Maximum value of ELFI is 100. Minimum value of ELFI is 0. Higher score indicates higher function.

    Time frame: 12 and 26 weeks after inclusion

Secondary outcomes

  1. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

    The questionnaire contains functional and symptom subscales. Maximum value for scales is 100 and minimum values is 0. A higher score indicates higher function for functional scales and more symptoms for symptom scales.

    Time frame: 12 and 26 weeks after inclusion

  2. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Elderly14 (EORTC QLQ-Eld14).

    The questionnaire contains functional scales and symptom scales. Maximum value for scales is 100 and minimum values is 0. A higher score indicates higher function for functional scales and more symptoms for symptom scales

    Time frame: 12 and 26 weeks after inclusion

  3. Handgrip strength

    Handgrip strength is measured in kilograms with a handgrip dynamometer

    Time frame: 12 and 26 weeks after inclusion

  4. 30-second chair stand test

    30-second chair stand test is measured in number of stand-up-and-sit-downs in 30 seconds

    Time frame: 12 and 26 weeks after inclusion

  5. Treatment toxicity

    Endpoint is assessed as prevalence of grade \> 1 adverse events according to Common Terminology Criteria for Adverse Events Version 5.0 at baseline, 12 and 26 weeks after inclusion

    Time frame: Baseline, 12 and 26 weeks after inclusion

  6. Adherence to hematological cancer treatment

    Alterations to original cancer treatment plan yes/no

    Time frame: 12 and 26 weeks after inclusion

  7. Polypharmacy yes/no

    Polypharmacy is defined as use of 5 or more daily medications

    Time frame: 12 and 26 weeks after inclusion

  8. Unplanned hospital admissions

    rates and hospital days

    Time frame: 26 and 52 weeks after inclusion

  9. Overall and cancer specific survival

    survival proportion and cancer specific survival proportion

    Time frame: 26 and 52 weeks after inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The IPD sharing plan is to assess the possibility of publishing IPD or part of IPD in a way that is allowed taken GDPR into account.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Mar 2026, 23 months after the start.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 23 months is below that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Apr 18, 2024
StartActual
Apr 2, 2024
Primary completionEst.
Mar 31, 2026
CompletionEst.
Sep 30, 2026
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06373471
Collaborators
Velux Fonden, Danish Cancer Research Foundation, The Dagmar Marshall Foundation
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Apr 2, 2024
Primary completion
Mar 31, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Apr 18, 2024

Study contacts

Henrik Frederiksen
Contact
henrik.frederiksen@rsyd.dk
+45 21849307
Nina Andersen
Contact
nina.andersen@rsyd.dk
+45 40437488
Henrik Frederiksen
principal investigator · Odense University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion